About us

Russian Developer and Manufacturer of Interventional Cardiology and Cardiovascular Surgery Products

2007 foundation of Angioline Interventional Device
2009 launch of Bare Metal Stent “Sinus” and Balloon Catheter “Colubris”
15 types of devices for interventional cardiology are being manufactured since 2011
2012 launch of Sirolimus-eluting Coronary Stent “Calipso”
2013 implementation of ISO 9001 and ISO 13485 Quality Management System Certificates
2017 successful results of the prospective randomised, single-blind, multicentral clinical trial "PATRIOT" of sirolimus-eluting coronary stent vs. everolimus-eluting coronary stent has been published
2018 the company's quality management system was certified with the requirements of the new international standard ISO 13485: 2016 & EN ISO 13485: 2016, the scope of the certificate was extended on endocardial products, surgical sutures with needles
$ 5 million annual insurance coverage
More than 140,000 stents are implanted as of April 2018
210 clinics in 63 Russian regions of registered endovascular procedures were a success
2400 implantations have been included into the register maintained by independent experts of The Moscow Department of Health N.V. Sklifosovsky Federal Research Institute of Emergency Medicine as a part of the study conducted in nine Russian clinics (Moscow, Novosibirsk, Barnaul, Tomsk, Krasnoyarsk, Vladivostok and Yaroslavl)
September 2017 Final stage of the PATRIOT clinical investigation: prospective randomized multicenter investigation into efficiency and safety of the CALIPSO sirolimus-eluting coronary stent vs XIENCE PRIME everolimus-eluting stent
98,7% of endovascular procedures included into the register were successful
Transcatheter Aortic Heart Valve, Cava Filter, Stent-Graft, LAA Occluder new developments at the stage of certification
Collaborative work of the company with the scientific community basis for the development of the innovative and affordable treatments

Подписавшись на рассылку новостей мы гарантируем, что будем отправлять не более одного - два письма в месяц. Основными темами рассылок будут достижения компании в области разработки оборудования и аксессуаров для ангиопластики.